Fractyl (United States)

Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study

Harith Rajagopalan, Alan D. Cherrington, Christopher C. Thompson et al. · Diabetes Care · 2016 · 206 citations

Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors

Alex Abramson, Morten Revsgaard Frederiksen, Andreas Vegge et al. · Nature Biotechnology · 2021 · 157 citations · Full text

Allergy, Immunology, Systemic Monoclonal Antibodies +9

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial

Geltrude Mingrone, Annieke C. Van Baar, Jacques Devière et al. · Gut · 2021 · 104 citations · Full text

Drinkable in situ-forming tough hydrogels for gastrointestinal therapeutics

Gary W. Liu, Matthew J. Pickett, Johannes Kuosmanen et al. · Nature Materials · 2024 · 90 citations · Full text

Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting

Rehan Haidry, Annieke C. Van Baar, Manoel Galvão Neto et al. · Gastrointestinal Endoscopy · 2019 · 61 citations · Full text

Medicine, Gastroenterology, Clinical Gastroenterology +5